DESCRIPTION OF THE DATA i. Description of the data
DESCRIPTION OF THE DATA processing
DESCRIPTION OF THE DATA. The following data elements cover students enrolled in the respective educational institutions from 2021 to 2024. Student Level Data. Student level data include demographic, performance, perceptual, and attendance data for students in schools participating in this Network. The manner and form in which the data are to be prepared is outlined in an addendum. This data is collected for the purpose of examining on-track drivers and the extent to which grant activities influence student opportunity and achievement. Data are collected triennially in the fall, winter, and spring of each project year (2022-2023)
DESCRIPTION OF THE DATA. The [TRIBE] authorizes IAD on behalf of the New Mexico Indian Affairs Department to collect the following data, consistent with protection of the rights and confidentiality of individuals and the tribe: Responses collected though the distribution of surveys to tribal law enforcement officers and service providers working within a tribe’s jurisdiction.
DESCRIPTION OF THE DATA. (1) At the request of the Tribal IV-D program signing this agreement, DCS shall release the following information related to a case certified for federal offset when necessary for processing and distributing federal offset funds:
DESCRIPTION OF THE DATA. The [NAME of TRIBE] provides authorization for the Albuquerque Area Southwest Tribal Epidemiology Center to access & store the data from the following tribal programs on its behalf and upon its request, consistent with protection of the rights and confidentiality of individuals and tribes: • [list tribal program(s) here]
DESCRIPTION OF THE DATA. The dataset consists of baseline or sequential clinical, laboratory and CT images of patients with COVID-19 Clinical data: age, gender, Weight, Length, Smoking, Comorbidity: Hypertension, cardias, pulmonary, renal (acute chronic), diabetes, active cancer (if yes: metastasis, treatment), other comorbidity, Hospital staff, Symptoms at hospital admission: body temperature, dyspnea, interval between first symptoms and hospitalization, Medication at drug admission, Participation to a clinical trial, name of experimental drugs. Laboratory data: Lactate Dehydrogenase, Creatine Kinase, Calcium, Urea, C-Reactive Protein, Lymphocytes (%, absolute numbers), Neutrophils, (%, absolute numbers), Images: Anonymized-coded CT in DICOM format Outcome: Severe disease (see definition herunder), Use of ventilator (if yes how long?), Shock or organ failure, death (if yes how many days after hospitalization), still hospitalized at the moment of data capture Definition of severe disease: Severe disease is defined as: Patients were labelled as having a “severe disease” if at least one of the following criteria were met during hospitalization.
